Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Innovation Council · Running

NIGHT Non-invasive Glucose Health Technology

Coordinator
DiaMonTech AG, Germany
Runs
1 October 2026 to 31 March 2028
Status
Running
EU funding
€2.5m
Total cost
—
Partners
1 organisations in 1 countries
Type
European Innovation Council
Grant agreement
101330206

What the project is doing

In the project's own words, from its summary on CORDIS.

Diabetes affects over 589 million people and remains a leading cause of severe complications including cardiovascular disease and blindness. Effective management relies on frequent glucose monitoring, yet current methods impose significant barriers. Self monitoring with finger pricks is painful, inconvenient, and stigmatizing, leading to poor compliance. Continuous glucose monitors (CGMs) have improved insights but remain invasive, requiring skin penetration, adhesives, and costly consumables.

They are also prone to malfunctions and cover only 2–4% of patients due to cost, discomfort, and technical complexity. Both approaches generate substantial biohazard waste, further limiting sustainability. DiaMonTech’s D-Pocket introduces the first truly non-invasive glucose monitoring device. Based on proprietary mid-infrared photothermal detection, the handheld sensor allows users to measure glucose levels painlessly, simply by placing a finger or wrist on the device.

The D-Pocket addresses the most cited barriers to regular monitoring: pain, anxiety, infection risk, and waste generation. Non-invasive monitoring increases daily measurement frequency and this translates into significant reductions in microvascular complications and improved long-term outcomes, as demonstrated in landmark diabetes trials. The D-Pocket is achieving better health outcomes for its primary target group - people with type 2 diabetes who currently rely on finger pricks.

The D-Pocket empowers millions to manage their disease more effectively, and contributes to healthier, longer lives. DiaMonTech AG is a medical technology company with the mission ""to improve the quality of life for everyone by unlocking health data"". It has received approximately EUR 25m in funding to date plus another ~EUR 10m during the EIC application phase and is currently seeking an additional EUR 2.5m grant and EUR 7.5m equity from the EIC to finalize development, achieve certification, and begin marketing the device.""

Who is involved

OrganisationCityCountryRole
DiaMonTech AGBerlinGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI